American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.
about
Drugs for the treatment of nausea and vomiting in adults in the emergency department settingNeurokinin-1 receptor antagonists for prevention of chemotherapy-related nausea and vomiting in adultsDrugs for the treatment of nausea and vomiting in adult patients in the emergency department settingSerotonin receptor antagonists for highly emetogenic chemotherapy in adultsSerotonin receptor antagonists for highly emetogenic chemotherapy in adultsNeurokinin-1 receptor antagonists for prevention of chemotherapy-related nausea and vomiting in adultsChinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patientsThe therapeutic potential of cannabis and cannabinoidsChemotherapy-and cancer-related nausea and vomitingPalonosetron (Aloxi): a second-generation 5-HT₃ receptor antagonist for chemotherapy-induced nausea and vomitingThe 5-HT3 receptor as a therapeutic targetNeurokinin-1 receptor antagonists for prevention of chemotherapy-related nausea and vomiting in adultsProphylactic Management of Radiation-Induced Nausea and VomitingRecent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive reviewFosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomitingFood restriction, refeeding, and gastric fill fail to affect emesis in musk shrews.Chemotherapy agent cisplatin induces 48-h Fos expression in the brain of a vomiting species, the house musk shrew (Suncus murinus).Synthetic and natural antioxidants attenuate cisplatin-induced vomitingCan administrative data be used to measure chemotherapy side effects?Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study.Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting.Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumoursA phase I pharmacokinetic study of PM00104 (Zalypsis) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors.Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.Review of palonosetron: emerging data distinguishing it as a novel 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting.Ramosetron hydrochloride for the prevention of cancer chemotherapy induced nausea and vomiting: The Indian experienceAnti-emetic drugs in oncology: pharmacology and individualization by pharmacogeneticsAssociation of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting.Antiemetics: American Society of Clinical Oncology clinical practice guideline update.Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomitingThe Role of Supportive Therapy in the Era of Modern Adjuvant Treatment - Current and Future Tools.Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis.Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009.Update and new trends in antiemetic therapy: the continuing need for novel therapies.Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomitingEvaluating the various phases of cisplatin-induced emesis in rats.Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents.
P2860
Q24186973-B586DE5A-2E42-41CF-A772-C8A58835EDC5Q24200792-3634EA1D-6EE4-49FE-91AF-DEEEB2681226Q24201285-EF337864-7213-40DA-A08D-6849E7C55D58Q24202033-CFD83779-DDF7-4F47-B5E5-C902DBB2DCA0Q24240511-3DE7364A-35BA-4098-BA34-7F6CC25277C8Q24243745-DC88F0C1-E0DB-4C2D-8690-656EC26A9BBBQ24245485-67B34421-E610-4C44-8036-D088F17BF617Q24600806-859107B5-B70B-46D0-9F02-27CF31B35FABQ24644831-877136F7-F059-4941-AF8A-0525D356B65BQ24669786-9A242324-7BA4-45C0-B923-4A30AD8873D2Q24681066-E9BD2F90-3BEB-4011-A393-8D23F0A39B0DQ26472106-281B97B5-3B1D-4250-ADC0-BB00E645C02CQ26783184-ADB4352E-FCC9-4112-A39C-197A994289F6Q28081186-4FDC6E5B-A441-4181-A3AA-2E9D75BDA50FQ28258863-01CE9D34-A273-42DD-A2EB-C7A9A8D509CCQ30433586-C4863FF1-60FD-4E83-95EC-9E505B927033Q30436557-02AA9B7D-DE25-4DD2-8ACE-5752E5D89EDAQ30834914-A6FD9387-1C91-4BA9-BD01-498391A377DDQ30877306-E6D796E4-3FD8-41E1-B3B2-5D3D0F94C528Q30973575-CBE6E69F-13C8-470E-8C49-9D16AB369120Q33158720-40E618D7-1C42-4BB8-B9CA-CE4DAF007447Q33286793-B058D8D7-7C58-4E9A-9FC1-C7EEFB67F4BFQ33400678-553F48CA-CCD5-4113-B159-6AC118FA9685Q33406206-9D928020-6B37-4DAA-9CAD-7A4934DE5711Q33407021-2B839A9F-0FE0-460B-A901-E18874C4F0C2Q33543954-859D920E-6F1E-4C38-B8B1-D38465A0D2FFQ33584510-C4352BF2-015B-4763-B5FD-02A69D62E5A3Q33834310-AA75628B-966E-4E7D-8CFC-74AB3673057BQ33992722-0EDD191B-A26B-4E50-9B7E-651E6C2806ACQ34013540-2BF2E80B-40AB-4D4D-A4CB-F26489D2FF63Q34030613-46A4BB3C-AD18-4B55-B200-9B04FAA45099Q34038796-CDBFB85E-72F9-4A55-9577-9572576266F3Q34095827-E875B684-FBB1-4C5D-AC97-85EB3F817258Q34121232-176CA374-E5A7-4562-ADB5-F8047A69A210Q34124711-7650C661-D77A-463D-9E49-34EC854E79CEQ34130599-8F086CD7-2C01-488D-B9F5-BB6EA9033795Q34143667-552A63D8-B21B-4D14-95CF-050338101DE4Q34239808-652FB9A2-D602-4F38-9CAB-9243973BA9FAQ34293135-0B1F567E-43B5-4547-BDB8-638FDCD9D2C3Q34327488-7C358A49-C166-40F3-A6C6-AF960B82AE9D
P2860
American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.
@ast
American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.
@en
type
label
American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.
@ast
American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.
@en
prefLabel
American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.
@ast
American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.
@en
P2093
P356
P1476
American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.
@en
P2093
Gary R Morrow
James M Koeller
Lawrence W Chinnery
Mark G Kris
Mark R Somerfield
Maurice J Chesney
Paul J Hesketh
Petra Feyer
Rebecca Clark-Snow
Richard J Gralla
P304
P356
10.1200/JCO.2006.06.9591
P407
P577
2006-05-22T00:00:00Z